---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-000190"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:35:18.893657+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Surrozen expects to start Phase 1 trials for SZN-1326 and SZN-043 in Q3 2022; nominates SZN-413 candidate

## Summary
- Expects to initiate Phase 1 clinical trials of SZN-1326 and SZN-043 in Q3 2022.
- Nominated SZN-413, a mono Fzd4 bi-specific antibody, for retinal vascular diseases including wet AMD and diabetic retinopathies.
- None of the product candidates have been tested in humans or gained regulatory approval.

## SEC filing metadata
- accession: 0000950170-22-000190
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017022000190/0000950170-22-000190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017022000190/srzn-20220110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-000190
- JSON: https://secwatch.observer/filing/0000950170-22-000190.json
- Plain text: https://secwatch.observer/filing/0000950170-22-000190.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.